C4 Therapeutics
CCCC
97 hedge funds and large institutions have $117M invested in C4 Therapeutics in 2025 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 26 increasing their positions, 38 reducing their positions, and 26 closing their positions.
49% more capital invested
Capital invested by funds: $78.2M → $117M (+$38.4M)
25% more call options, than puts
Call options by funds: $806K | Put options by funds: $645K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.2% less ownership
Funds ownership: 77.02% → 73.82% (-3.2%)
5% less funds holding
Funds holding: 102 → 97 (-5)
19% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 26
32% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 38
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$4.55M |
| 2 |
Millennium Management
New York
|
+$2M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$1.16M |
| 4 |
SC
Shay Capital
New York
|
+$1.01M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$899K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$6.17M |
| 2 |
O
OrbiMed
New York
|
-$3.83M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$1.23M |
| 4 |
Goldman Sachs
New York
|
-$1.01M |
| 5 |
Jane Street
New York
|
-$694K |
CCCC Hedge Fund Activity: Q3 2025 in Review
97 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in C4 Therapeutics (CCCC) for Q3 2025, worth a combined $117M — up 49% from $78.2M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of CCCC and 21 opened new positions — a net loss of 5 holders — while 38 trimmed existing stakes and 26 added.
The largest buyer was Silverarc Capital Management, opening a new position worth an estimated $4.55M. The largest seller was Wasatch Advisors, cutting an estimated $6.17M.
- 97 institutional investors held C4 Therapeutics (CCCC) as of Q3 2025, down from 102 in Q2 2025.
- Funds reported $117M of C4 Therapeutics stock for Q3 2025, up 49% quarter-over-quarter.
- 21 funds opened new C4 Therapeutics positions in Q3 2025 and 26 closed out, a net change of -5 holders.
- The largest C4 Therapeutics buyer in Q3 2025 was Silverarc Capital Management, an estimated $4.55M added.
- The largest C4 Therapeutics seller in Q3 2025 was Wasatch Advisors, an estimated $6.17M sold.
Based on aggregated 13F filings for Q3 2025.